Dynamic modulation of inhibition ability following repeated exposures to morphine in macaque monkey

Sadegh Ghasemian1,2, Marzieh M Vardanjani1,2, Vahid Sheibani1,2

  • 1Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.

Abstract

Insights

Repeated morphine exposure dynamically alters cognitive control in primates. Initial exposure enhances inhibition, while repeated exposure impairs it, offering potential intervention points for opioid addiction.

Area of Science:

  • Cognitive Neuroscience
  • Neuropharmacology
  • Addiction Research

Background:

  • Opioid addiction is linked to deficits in cognitive control, especially inhibition.
  • The developmental trajectory and interaction of these deficits with opioid exposure remain unclear.

Purpose of the Study:

  • To investigate alterations in inhibition ability during repeated morphine exposure using a primate model.
  • To understand the temporal dynamics of cognitive control changes in relation to opioid use.

Main Methods:

  • Macaque monkeys (Macaca mulatta) were trained on a stop-signal task.
  • Inhibition ability was assessed before, during, and after morphine exposure, including abstinent periods.
  • Morphine-induced conditioned place preference (CPP) was measured to assess long-term behavioral effects.

Main Results:

  • Initial morphine exposure significantly enhanced inhibition compared to baseline.
  • Repeated morphine exposure led to a significant attenuation of inhibition.
  • Morphine-induced CPP was consistently observed throughout the exposure period.

Conclusions:

  • Repeated, scheduled morphine exposure induces dynamic changes in primate cognitive control.
  • Early enhancement of inhibition presents a potential window for therapeutic intervention in opioid addiction.
  • Understanding these dynamics is crucial for preventing the progression of addiction characterized by disinhibition.

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
1.6K
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
776